Yuhan Corporation has signed a memorandum of understanding with Syntekabio Inc. to develop new drugs using genomic big data and an artificial intelligence (AI) platform. Under the agreement, Yuhan and Syntekabio will promote joint research on discovering biological markers or indicators of certain biological condition by analyzing patients genome properties and searching for new drug candidate materials using an AI-based platform. This agreement enables Yuhan and Syntekabio to develop new drugs using genomic big data and an artificial intelligence (AI) platform.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9,300 KRW | -1.59% | -4.42% | -34.69% |
05-23 | Syntekabio to Showcase Advanced AI Drug Discovery Technologies at BIO International Convention 2024 | CI |
05-07 | Syntekabio Announces to Showcase Biologics Discovery Platform At PEGS Boston | CI |
1st Jan change | Capi. | |
---|---|---|
-34.69% | 104M | |
-14.46% | 25.65B | |
+17.85% | 1.33B |
- Stock Market
- Equities
- A226330 Stock
- News SyntekaBio, Inc.
- Yuhan Enters into Agreement with Syntekabio